Protagonist Therapeutics ... (PTGX)
NASDAQ: PTGX
· Real-Time Price · USD
54.66
-1.71 (-3.03%)
At close: Jun 16, 2025, 3:59 PM
54.66
0.01%
After-hours: Jun 16, 2025, 06:00 PM EDT
-3.03% (1D)
| Bid | 54 |
| Market Cap | 3.39B |
| Revenue (ttm) | 207.8M |
| Net Income (ttm) | 56.19M |
| EPS (ttm) | 0.78 |
| PE Ratio (ttm) | 70.07 |
| Forward PE | -939.33 |
| Analyst | Buy |
| Ask | 59.75 |
| Volume | 589,913 |
| Avg. Volume (20D) | 1,062,592 |
| Open | 56.40 |
| Previous Close | 56.37 |
| Day's Range | 54.30 - 56.99 |
| 52-Week Range | 30.67 - 60.60 |
| Beta | 2.25 |
About PTGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PTGX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+45.89%
Protagonist Therapeutics shares are trading higher...
Unlock content with
Pro Subscription
3 months ago
+2.42%
Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.
1 month ago · accessnewswire.com
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePositive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call ...
